BRUCELLOSIS VACCINES MARKET ANALYSIS

The increasing adoption of strategies such as acquisitions & agreement by key players is expected to drive the market growth over the forecast period. For instance, in September 2020, Hester Biosciences Limited signed an agreement with IVRI (Indian Veterinary Research Institute), an institute under the Indian Council of Agricultural Research (ICAR), to acquire Brucella vaccine technology for developing the Brucella Abortus S19 Delta Pevaccine from IVRI Hester, which manufactures the conventional Brucella Abortus S19 vaccine and supplies it to all the states in India. The S19 Delta Per new generation vaccine technology developed by IVRI will be a step forward towards developing a Brucella vaccine with enhanced immunogenicity and safety, assuring lifelong immunity with a single shot in calf-hood. 

The global Brucellosis Vaccines Market is estimated to be valued at US$ 224.64 million in 2022 and expected to exhibit a CAGR of 4.7% over the forecast period (2022-2030)

Figure 1. Global Brucellosis Vaccines Market Share (%) in Terms of Value, By Region, 2022

To learn more about this report, request a free sample copy

Increasing investments by key players in market for expansion of brucellosis manufacturing facilities is expected to drive market growth over the forecast period.

For instance, in August 2019, Biovet Private Ltd, an animal health vaccine producing company located in Karnataka, India, announced that it will invest US$ 26,212,600 (Rs 200 crore) for expanding its foot & mouth and brucellosis vaccine manufacturing facilities in Malur, Karnataka, India. This is expected to drive market growth over the forecast period.

Figure 2. Global Brucellosis Vaccines Market Share (%), by Type, 2022

To learn more about this report, request a free sample copy

Global Brucellosis Vaccines Market: Restraint

Drawbacks associated with use of brucellosis vaccines is expected to act as a restraint for the global brucellosis vaccines market growth over the forecast period. For instance, according to an article published by the Journal of Veterinary Science, an international, peer-reviewed, open-access journal of veterinary medicine, in August 2017, currently available brucellosis vaccines exhibit one or more major drawbacks such as residual virulence and serodiagnostic interference. Moreover, according to an article published by the journal Veterinary Research, an open access journal that publishes high quality novel research and review articles, in July 2015, although the available vaccines are effective in controlling brucellosis, they have numerous drawbacks such as interference with diagnostic tests, pathogenicity for humans, and potential to cause abortion in pregnant animals, among others.

Key Players

Major players operating in the global brucellosis vaccines market include Merck & Co., Inc., CZ Vaccines, Colorado Serum Company, Indian Immunologicals Ltd., Hester Biosciences Limited, Veterinary Technologies Corporation, Jordan Bio-industries Center, Laboratorios Tornel, Fivet Animal Health, and VETAL Animal Health Products Inc.